6TH ANNUAL ACHONDROPLASIA & SKELETAL DYSPLASIA RESEARCH CONFERENCE
SOURCE: Children’s National Hospital – Vosoritide’s first global phase 2 study showed an average increased growth rate of 1.8 cm per year in children with hypochondroplasia, a genetic cause of…
SOURCE: https://bridgebio.com/news/bridgebio-announces-first-child-dosed-with-infigratinib-in-propel-3-its-phase-3-clinical-trial-in-children-with-achondroplasia/ – BridgeBio has dosed the first child in PROPEL 3, a one-year, 2:1 randomized, placebo-controlled Phase 3 pivotal trial evaluating the efficacy and safety of infigratinib in children…
The following press release was obtained from BioMarin.com. To learn more about BioMarin, VOXZOGO®, vosorotide, and their other pipelines and research for achondroplasia and other skeletal dysplasias, click here. Expanded…
The following press release was obtained from BridgeBio.com, parent company of QED therapeutics. To learn more about QED and their research surrounding achondroplasia and other skeletal dysplasias, click here. PALO ALTO, Calif., June…
In the highest dose level (Cohort 5, 0.25 mg/kg once daily), the mean change from baseline in annualized height velocity (AHV) at six months was +3.03 cm/yr (p = 0.0022)…